Pharmacogenetics of antidepressant response: A polygenic approach

Judit García-González, Katherine E. Tansey, Joanna Hauser, Neven Henigsberg, Wolfgang Maier, Ole Mors, Anna Placentino, Marcella Rietschel, Daniel Souery, Tina Žagar, Piotr M. Czerski, Borut Jerman, Henriette N. Buttenschøn, Thomas G. Schulze, Astrid Zobel, Anne Farmer, Katherine J. Aitchison, Ian Craig, Peter McGuffin, Michel GiupponiNader Perroud, Guido Bondolfi, David Evans, Michael O'Donovan, Tim J. Peters, Jens R. Wendland, Glyn Lewis, Shitij Kapur, Roy Perlis, Volker Arolt, Katharina Domschke, Gerome Breen, Charles Curtis, Lee Sang-Hyuk, Carol Kan, Stephen Newhouse, Hamel Patel, Bernhard T. Baune, Rudolf Uher, Cathryn M. Lewis, Chiara Fabbri

Research output: Contribution to journalArticle (Academic Journal)

35 Citations (Scopus)
233 Downloads (Pure)

Abstract

AbstractBackground Major depressive disorder (MDD) has a high personal and socio-economic burden and > 60% of patients fail to achieve remission with the first antidepressant. The biological mechanisms behind antidepressant response are only partially known but genetic factors play a relevant role. A combined predictor across genetic variants may be useful to investigate this complex trait. Methods Polygenic risk scores (PRS) were used to estimate multi-allelic contribution to: 1) antidepressant efficacy; 2) its overlap with MDD and schizophrenia. We constructed PRS and tested whether these predicted symptom improvement or remission from the GENDEP study (n = 736) to the STAR*D study (n = 1409) and vice-versa, including the whole sample or only patients treated with escitalopram or citalopram. Using summary statistics from Psychiatric Genomics Consortium for MDD and schizophrenia, we tested whether PRS from these disorders predicted symptom improvement in GENDEP, STAR*D, and five further studies (n = 3756). Results No significant prediction of antidepressant efficacy was obtained from PRS in GENDEP/STAR*D but this analysis might have been underpowered. There was no evidence of overlap in the genetics of antidepressant response with either MDD or schizophrenia, either in individual studies or a meta-analysis. Stratifying by antidepressant did not alter the results. Discussion We identified no significant predictive effect using PRS between pharmacogenetic studies. The genetic liability to MDD or schizophrenia did not predict response to antidepressants, suggesting differences between the genetic component of depression and treatment response. Larger or more homogeneous studies will be necessary to obtain a polygenic predictor of antidepressant response.
Original languageEnglish
Pages (from-to)128-134
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume75
Early online date31 Jan 2017
DOIs
Publication statusPublished - 3 Apr 2017

Keywords

  • Antidepressant
  • Pharmacogenomics
  • Polygenic risk scores
  • Major depressive disorder
  • Schizophrenia

Fingerprint Dive into the research topics of 'Pharmacogenetics of antidepressant response: A polygenic approach'. Together they form a unique fingerprint.

  • Cite this

    García-González, J., Tansey, K. E., Hauser, J., Henigsberg, N., Maier, W., Mors, O., Placentino, A., Rietschel, M., Souery, D., Žagar, T., Czerski, P. M., Jerman, B., Buttenschøn, H. N., Schulze, T. G., Zobel, A., Farmer, A., Aitchison, K. J., Craig, I., McGuffin, P., ... Fabbri, C. (2017). Pharmacogenetics of antidepressant response: A polygenic approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 75, 128-134. https://doi.org/10.1016/j.pnpbp.2017.01.011